Correlation between ovarian chocolate cyst and serum carbohydrate antigen 125 level and the effect of ultrasound‐guided interventional sclerotherapy on serum carbohydrate antigen 125 level

Siming Wang, Huaiqiu Cai, Xiao‐Qiu Dong, Qiu‐Lan Fan, Lulu Wang, Xiao‐Hui Shao, Liwei Zhang
In: Journal of Obstetrics and Gynaecology Research · 2014 · vol. 41(1) , pp. 92–98 · doi:10.1111/jog.12491 · PMID:25159825 · W1603338560
article OA: closed CC0 ⤵ 13 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Ovarian chocolate cyst CA-125 levels correlate with disease duration, dysmenorrhea, cyst diameter, and wall thickness, and ultrasound-guided sclerotherapy significantly reduces elevated CA-125 levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: This study was to investigate the correlation between ovarian chocolate cysts and serum carbohydrate antigen (CA)-125 levels and to demonstrate the effect of ultrasound-guided interventional sclerotherapy (UGIS) on serum CA-125 levels. METHODS: Based on the serum CA-125 level, as determined by chemiluminescence detection prior to UGIS, 105 patients with ovarian chocolate cysts were divided into the normal group (CA-125 ≤ 35 U/mL, 45 patients) and the abnormal group (35 U/mL < CA-125 ≤ 200 U/mL, 60 patients). There were six clinical indicators including age, disease duration, dysmenorrhea history, child-bearing history, abortion history and surgical history. The ultrasonography characteristics were cyst diameter, cyst wall thickness and the side on which the cyst occurred. The correlations between serum CA-125 levels pretreatment and the clinical indicators and ultrasonography characteristics was analyzed. The serum CA-125 levels pretreatment, 3 months post-treatment and 6 months post-treatment were compared. RESULTS: The pretreatment serum CA-125 levels of the 105 patients positively correlated with disease duration (r = 0.3932, P = 0.0040), dysmenorrhea history (r = 0.2351, P = 0.0111), cyst diameter (r = 0.3415, P < 0.0001) and cyst wall thickness (r = 0.4263, P < 0.0001). Compared with the pretreatment level, the mean serum CA-125 level in the abnormal group at 3 months post-treatment was significantly lower (P < 0.01), and at 6 months post-treatment, the mean serum CA-125 level had decreased to a normal level (P < 0.01). CONCLUSION: UGIS significantly decreased abnormal serum CA-125 levels in patients with ovarian chocolate cysts.

My notes (saved in your browser only)

Condition tags

dysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (32)

Cited by (13)

Source provenance

openalex
last seen: 2026-05-10T11:14:57.310873+00:00
unpaywall
last seen: 2026-06-04T02:00:05.705006+00:00
License: CC0 · commercial use OK